Idiopathic detrusor sphincter dyssynergia in neurologically normal patients with voiding abnormalities.
Jørgensen TM, Djurhuus JC, Schrøder HD.
Eur Urol. 1982;8(2):107-10. doi: 10.1159/000473490.
Idiopathic detrusor-urethral dyssynergia in dogs: a retrospective analysis of 22 cases.
Díaz Espiñeira MM, Viehoff FW, Nickel RF.
J Small Anim Pract. 1998 Jun;39(6):264-70. doi: 10.1111/j.1748-5827.1998.tb03648.x.
Chinese botulinum toxin A for the treatment of lower urinary tract dysfunction: It works just as well.
Zhang F, Liu Q, Liao L, Li X, Zhang X.
Bladder (San Franc). 2022 Sep 14;9(1):e47. doi: 10.14440/bladder.2022.847. eCollection 2022.
Botulinum toxin as a new therapy option for voiding disorders: current state of the art.
Leippold T, Reitz A, Schurch B.
Eur Urol. 2003 Aug;44(2):165-74. doi: 10.1016/s0302-2838(03)00250-1.
Current and potential urological applications of botulinum toxin A.
Jiang YH, Liao CH, Kuo HC.
Nat Rev Urol. 2015 Sep;12(9):519-33. doi: 10.1038/nrurol.2015.193. Epub 2015 Aug 11.
[THE USE OF BOTULINUM TOXIN IN UROLOGY].
Anis O, Kitrey ND.
Harefuah. 2021 Sep;160(9):615-618.
Botulinum toxin for conditions of the female pelvis.
El-Khawand D, Wehbe S, Whitmore K.
Int Urogynecol J. 2013 Jul;24(7):1073-81. doi: 10.1007/s00192-012-2035-1. Epub 2013 Jan 24.
Botulinum toxin in urology: evaluation using an evidence-based medicine approach.
Smith CP, Somogyi GT, Boone TB.
Nat Clin Pract Urol. 2004 Nov;1(1):31-7. doi: 10.1038/ncpuro0034.
An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C.
Eur Urol. 2014 May;65(5):981-90. doi: 10.1016/j.eururo.2013.10.033. Epub 2013 Nov 1.
Botulinum toxin injection for lower urinary tract dysfunction.
Kuo YC, Kuo HC.
Int J Urol. 2013 Jan;20(1):40-55. doi: 10.1111/j.1442-2042.2012.03035.x. Epub 2012 May 9.
